# An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 1 Diabetes Mellitus

> **NCT00542724** · PHASE3 · COMPLETED · sponsor: **Biodel** · enrollment: 462 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** VIAject™
- **DRUG:** Regular Human Insulin

## Key facts

- **NCT ID:** NCT00542724
- **Lead sponsor:** Biodel
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2008-07
- **Final completion:** —
- **Target enrollment:** 462 (ACTUAL)
- **Last updated:** 2015-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00542724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00542724, "An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 1 Diabetes Mellitus". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT00542724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*